Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : INF108
Therapeutic Area : Gastroenterology
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Infinant Health Announces Submission of Orphan Drug Designation Application
Details : Infinant Health's patented drug candidate is a Bifidobacterium longum subspecies infantis strain, INF108, being developed for the prevention of necrotizing enterocolitis in pre-term infants.
Brand Name : INF108
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 02, 2024
Lead Product(s) : INF108
Therapeutic Area : Gastroenterology
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?